Personalized Bilayer Tablets with Integrated Wearable and Genomic Diagnostics

The present disclosure relates to a next-generation bilayer tablet system that integrates wearable devices, machine learning algorithms, and genomics-based diagnostics to provide personalized treatment for patients suffering from the common cold or flu.

The original patent disclosed bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, but lacked real-time monitoring and adjustment capabilities, as well as personalized treatment approaches. The new inventive concept addresses these limitations by incorporating wearable devices and genomics-based diagnostics to optimize the dissolution rate and stability of the active pharmaceutical ingredients.

The system comprises a bilayer tablet comprising acetylsalicylic acid and pseudoephedrine, and a wearable device that monitors the user's vital signs and environmental conditions in real-time. The wearable device adjusts the dissolution rate of the bilayer tablet accordingly, ensuring optimal treatment. Additionally, the system includes a genomics-based diagnostic tool that predicts the optimal dosage and dissolution rate of the bilayer tablet based on the patient's genetic profile. The bilayer tablet may also include a microelectromechanical systems (MEMS) device that releases a stabilizing agent in response to changes in temperature or humidity, maintaining the chemical stability of the active pharmaceutical ingredients. Furthermore, the system may utilize machine learning algorithms to predict and prevent potential degradation pathways of the active pharmaceutical ingredients.

The new inventive concept introduces the integration of wearable devices, machine learning algorithms, and genomics-based diagnostics with bilayer tablets, providing a paradigm shift in personalized treatment approaches. The real-time monitoring and adjustment capabilities, as well as the use of genomics-based diagnostics, represent a significant departure from the original patent's limitations.

Alternative embodiments of the inventive concept may include the use of different wearable devices, such as smartwatches or fitness trackers, or the incorporation of other diagnostic tools, such as proteomics-based diagnostics. Additionally, the bilayer tablet may be replaced with other dosage forms, such as capsules or patches, to provide further flexibility in the system.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine and precision healthcare. The system's ability to provide real-time monitoring and adjustment capabilities, as well as personalized treatment approaches, may lead to improved treatment outcomes and increased patient satisfaction.